Navigation Links
FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
Date:4/29/2008

BURLINGTON, Mass., April 29 /PRNewswire/ -- InfraReDx, Inc. announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its catheter-based LipiScan(TM) Coronary Imaging System. The LipiScan device uses near-infrared spectroscopy to identify lipid core containing plaques of interest in the coronary arteries in patients already undergoing cardiac catheterization. Such plaques, which cannot be detected by commonly used tests such as a treadmill examination and even coronary angiography, are suspected to be the cause of most sudden cardiac deaths and non-fatal heart attacks.

The availability of this novel tool culminates a decade-long biomedical engineering effort to create an instrument that could perform spectroscopy in the arteries of patients with coronary artery disease. The identification of the chemical composition of coronary plaques is expected to be of value to cardiologists in the selection of medical, stenting or surgical therapy for coronary lesions. The device is also expected to be of value to the pharmaceutical industry as a means to assess the effect of novel anti-atherosclerotic agents on lipid core plaque burden.

"The InfraReDx team is pleased that the LipiScan System has been validated in tissue samples and a clinical study and has been cleared by the FDA for use in patients. We understand the great potential of interventional cardiology and anticipate that this novel tool will assist physicians with the complex decisions they face in the management of patients with coronary artery disease," says James E. Muller, M.D., cardiologist, co-founder, President and CEO of InfraReDx, Inc.

Dr. Muller noted that the creation of this novel device was greatly aided by the support and expertise of Sanderling Ventures of San Mateo, California. "Robert McNeil, Ph.D., Chairman of the Board of InfraReDx, and Timothy Mills, Ph.D., InfraReDx Board member are managing directors of Sanderling and both have extensive experience in medical device development," said Dr. Muller. "Sanderling was a seed investor in Advanced Cardiovascular Systems, a company that pioneered development of balloon angioplasty and was acquired by Guidant."

"While angioplasty and stenting were major advances, stenting has not been capable of preventing heart attacks due to the difficulty in identifying lesions likely to rupture and cause thrombosis. With the development of the LipiScan Coronary Imaging System, Sanderling is again contributing to a major step forward in providing a useful tool with which interventional cardiologists may improve the care of cardiac patients."

"There is a real unmet medical need to identify lipid core containing plaques of interest in the coronary arteries, which before now we could not do," says James Goldstein, M.D., Director of Research and Education at William Beaumont Hospital in Royal Oak, Michigan, who is also an investigator in the SPECTACL clinical trial for the device and a consultant for InfraReDx. "The ability to detect lipid core containing plaques of interest may go a long way in providing information to help prevent heart attacks in the near future."

How the LipiScan Coronary Imaging System Works

Near-infrared (NIR) spectroscopy is commonly used to measure the chemical composition of unknown substances. The LipiScan Coronary Imaging System utilizes advanced optical technology, much of it developed for telecom uses, to deliver and retrieve NIR light from coronary plaques. The light reflected back at different wavelengths is analyzed to detect the chemical composition of the coronary plaques. At the completion of the catheter pullback, the LipiScan console instantly displays the scan results on a "chemogram," a digital color-coded map of the location and intensity of lipid core containing plaques of interest in the artery. A Lipid Core Burden Index is also reported, which is a measure of the total amount of lipid core containing plaques of interest in the coronary artery. The LipiScan catheter interrogates each artery in less than 2 minutes and does not require the interruption of the flow of blood.

Successful Clinical Trial Results

The SPECTACL clinical trial documented the similarity of near-infrared spectra obtained from 106 patients undergoing coronary angiography compared to spectra obtained in autopsy specimens in which the gold-standard of histology was available. For more information, visit the InfraReDx website at http://www.infraredx.com.

About InfraReDx, Inc.

InfraReDx, Inc. is a privately-owned medical device company with expertise in near-infrared (NIR) spectroscopic technology and its application to coronary imaging. The company, located in Burlington, MA, was founded in 1998 to meet the unmet medical need for the detection and identification of lipid core containing plaques of interest in the coronary arteries. To meet this medical need, the Company developed The LipiScan Coronary Imaging System, an easy-to-use, catheter-based coronary imaging system that uses near-infrared spectroscopic technology to detect and characterize the composition of coronary artery plaques in patients undergoing catheterization. Funding for the development of the LipiScan System has been provided by a group of over 80 private investors and Sanderling Ventures. A Series C Funding round in 2007 raised $17 million. For more information, visit the InfraReDx website at http://www.infraredx.com.

InfraReDx Company Contacts:

Investor Contact:

Andrew Jordan, Chief Financial Officer

InfraReDx, Inc.

(781) 221-0053 x. 229

ajordan@infraredx.com

Media Contact:

Diane Kemp, Marketing Manager

InfraReDx, Inc.

(781) 221-0053 x. 341

dkemp@infraredx.com


'/>"/>
SOURCE InfraReDx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
2. Chinese SFDA Grants Immtech Fast Track Status
3. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
4. NTMir Announces Research Grants for Epidemiology and Household Water as Source of Infection
5. FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. FDA Grants Priority Review for ACIPHEX(R) (rabeprazole sodium) sNDA for Short-Term Treatment of GERD in Adolescents
8. FDA Grants Priority Review for PROMACTA(R) (eltrombopag)
9. FDA Grants NeoVistas Request to Expand CABERNET Trial to 30 Sites in the U.S.
10. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
11. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Research and Markets has announced the addition of ... report to their offering. ... Traditional medical devices include devices (e.g., ... implantables, large endoscopes, needle based drug delivery, lab based diagnostics ... to three decades for the treatment and management of various ...
(Date:2/16/2017)... -- DaVita Inc. (NYSE: DVA ) today announced ... Net income attributable to DaVita Inc. for ... million, or $0.80 per share and $880 million, or $4.29 ... to DaVita Inc. for the quarter and year ended December ... million, or $0.98 per share, and $789 million, or $3.85 ...
(Date:2/16/2017)... 16, 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ... today announced that executive management will participate in the ... February 22-23, 2017. Adrian Adams , Chief Executive ... 1:35 p.m. local time on Wednesday, February 22, 2017. ... the event may be accessed from the Investors section ...
Breaking Medicine Technology:
(Date:2/19/2017)... ... ... Braun Industries will be participating as an exhibitor at EMS Today 2017. ... 23-25, 2017 at the Calvin L. Rampton Salt Palace Convention Center in Salt Lake ... on display. , “JEMS is a leader in EMS news and education. ...
(Date:2/19/2017)... ... February 19, 2017 , ... ... in better care, and MEDfx and the Delaware Health Information Network (DHIN) have ... As the nation’s first state-wide health information exchange, DHIN stores and shares real-time ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... Axendia, **FDAnews Free Webinar**, March 1, 2017 — 1:30 p.m. – 2:30 ... regulatory burden? Pay dividends in enhanced and predictable product performance? Streamline processes ...
(Date:2/18/2017)... ... 17, 2017 , ... Butler Mobility invited Ken Matthews to visit its manufacturing ... Ken was impressed with the safety and reliability of the Stannah Stairlift as ... show. This endorsement by Ken Matthews can be heard on News Radio WHP ...
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter ... Show on the Pet Life Radio network. The episode, which was posted this ... topics including: what factors led to Park Cities Pet Sitter’s being awarded the 2017 ...
Breaking Medicine News(10 mins):